Terms: = Ovarian cancer AND TOP2A, TOP2, TP2A
49 results:
1. top2a modulates signaling via the AKT/mTOR pathway to promote ovarian cancer cell proliferation.
Zhang K; Zheng X; Sun Y; Feng X; Wu X; Liu W; Gao C; Yan Y; Tian W; Wang Y
Cancer Biol Ther; 2024 Dec; 25(1):2325126. PubMed ID: 38445610
[TBL] [Abstract] [Full Text] [Related]
2. Identification of Core Genes Shared by Endometrial cancer and ovarian cancer Using an Integrated Approach.
Ke Y; Zhuang X; You L
Cell Mol Biol (Noisy-le-grand); 2022 Sep; 68(9):140-145. PubMed ID: 36905262
[TBL] [Abstract] [Full Text] [Related]
3. A first-in-class clinical G-quadruplex-targeting drug. The bench-to-bedside translation of the fluoroquinolone QQ58 to CX-5461 (Pidnarulex).
Xu H; Hurley LH
Bioorg Med Chem Lett; 2022 Dec; 77():129016. PubMed ID: 36195286
[TBL] [Abstract] [Full Text] [Related]
4. Robust prognostic model based on immune infiltration-related genes and clinical information in ovarian cancer.
Zhang X; Kong W; Gao M; Huang W; Peng C; Huang Z; Xie Z; Guo H
J Cell Mol Med; 2022 Jul; 26(13):3659-3674. PubMed ID: 35735060
[TBL] [Abstract] [Full Text] [Related]
5. Integrated Bioinformatics Analysis for Identification of the Hub Genes Linked with Prognosis of ovarian cancer Patients.
Li X; Wang Q; Wu Z; Zheng J; Ji L
Comput Math Methods Med; 2022; 2022():5113447. PubMed ID: 35047055
[TBL] [Abstract] [Full Text] [Related]
6. Rhophilin rho GTPase binding protein 1-antisense RNA 1 (RHPN1-AS1) promotes ovarian carcinogenesis by sponging microRNA-485-5p and releasing DNA topoisomerase II alpha (
Zhou Y; Li J; Yang X; Song Y; Li H
Bioengineered; 2021 Dec; 12(2):12003-12022. PubMed ID: 34787052
[TBL] [Abstract] [Full Text] [Related]
7. Bioinformatic analysis of key pathways and genes shared between endometriosis and ovarian cancer.
Ni L; Chen Y; Yang J; Chen C
Arch Gynecol Obstet; 2022 May; 305(5):1329-1342. PubMed ID: 34727222
[TBL] [Abstract] [Full Text] [Related]
8. DFF40 deficiency in cancerous T cells is implicated in chemotherapy drug sensitivity and resistance through the regulation of the apoptotic pathway.
Kulbay M; Johnson B; Fiola S; Diaz RJ; Bernier J
Biochem Pharmacol; 2021 Dec; 194():114801. PubMed ID: 34678222
[TBL] [Abstract] [Full Text] [Related]
9. Explore the potential molecular mechanism of polycystic ovarian syndrome by protein-protein interaction network analysis.
Chen Q; Zheng B; Du S; Lin Y
Taiwan J Obstet Gynecol; 2021 Sep; 60(5):807-815. PubMed ID: 34507653
[TBL] [Abstract] [Full Text] [Related]
10. RHPN1‑AS1 promotes ovarian carcinogenesis by sponging miR‑6884‑5p thus releasing top2a mRNA.
Cui S; Li F
Oncol Rep; 2021 Oct; 46(4):. PubMed ID: 34414458
[TBL] [Abstract] [Full Text] [Related]
11. Integrative analysis of key candidate genes and signaling pathways in ovarian cancer by bioinformatics.
Dong C; Tian X; He F; Zhang J; Cui X; He Q; Si P; Shen Y
J Ovarian Res; 2021 Jul; 14(1):92. PubMed ID: 34253236
[TBL] [Abstract] [Full Text] [Related]
12. ARID1A regulates R-loop associated DNA replication stress.
Tsai S; Fournier LA; Chang EY; Wells JP; Minaker SW; Zhu YD; Wang AY; Wang Y; Huntsman DG; Stirling PC
PLoS Genet; 2021 Apr; 17(4):e1009238. PubMed ID: 33826602
[TBL] [Abstract] [Full Text] [Related]
13. Design, synthesis and antiproliferative evaluation of new tricyclic fused thiazolopyrimidines targeting topoisomerase II: Molecular docking and apoptosis inducing activity.
Nemr MTM; Sonousi A; Marzouk AA
Bioorg Chem; 2020 Dec; 105():104446. PubMed ID: 33171405
[TBL] [Abstract] [Full Text] [Related]
14. Bioinformatics analysis of gene expression profile of serous ovarian carcinomas to screen key genes and pathways.
Fei H; Chen S; Xu C
J Ovarian Res; 2020 Jul; 13(1):82. PubMed ID: 32693821
[TBL] [Abstract] [Full Text] [Related]
15. The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and top2.
Marzi L; Sun Y; Huang SN; James A; Difilippantonio S; Pommier Y
Mol Cancer Ther; 2020 Aug; 19(8):1589-1597. PubMed ID: 32430490
[TBL] [Abstract] [Full Text] [Related]
16. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract] [Full Text] [Related]
17. Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis.
Shen J; Yu S; Sun X; Yin M; Fei J; Zhou J
J Ovarian Res; 2019 Nov; 12(1):110. PubMed ID: 31729978
[TBL] [Abstract] [Full Text] [Related]
18. Genomic heterogeneity in peritoneal implants: A differential analysis of gene expression using nanostring Human cancer Reference panel identifies a malignant signature.
Mhawech-Fauceglia P; Izevbaye I; Spindler T; Wang G; Hwang H; Samrao D; Elishaev E; Maxwell GL; Lawrenson K; Darcy KM
Gynecol Oncol; 2020 Jan; 156(1):6-12. PubMed ID: 31711656
[TBL] [Abstract] [Full Text] [Related]
19. Modulation of selenium-dependent glutathione peroxidase activity enhances doxorubicin-induced apoptosis, tumour cell killing and hydroxyl radical production in human NCI/ADR-RES cancer cells despite high-level P-glycoprotein expression.
Doroshow JH; Juhasz A
Free Radic Res; 2019 Aug; 53(8):882-891. PubMed ID: 31290351
[TBL] [Abstract] [Full Text] [Related]
20. top2a as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers.
Ghisoni E; Maggiorotto F; Borella F; Mittica G; Genta S; Giannone G; Katsaros D; Sciarrillo A; Ferrero A; Sarotto I; Erriquez J; Di Renzo MF; Aglietta M; Valabrega G
J Ovarian Res; 2019 Feb; 12(1):17. PubMed ID: 30760286
[TBL] [Abstract] [Full Text] [Related]
[Next]
